Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Clinical Trials on Detection of Lung Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells
Sponsor: HKGepitherapeutics
Terminated
Encountered technical issues with blood plasma samples received from the hospital.
A observational or N/A phase clinical study on Lung Cancer and Lung Cancer, Nonsmall Cell, this trial is terminated or withdrawn. The trial is conducted by HKGepitherapeutics and has accumulated 13 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2024 — Jul 2024 [monthly]
Terminated
-
May 2022 — Jan 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Dec 2021 — May 2022 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Recruiting
-
Sep 2019 — Jun 2020 [monthly]
Recruiting
-
Nov 2018 — Sep 2019 [monthly]
Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- HKGepitherapeutics
- Kazakh Research Institute of Oncology & Radiology
For direct contact, visit the study record on ClinicalTrials.gov .